US Patent Issued to Ablynx, Sanofi on Aug. 18 for "Polypeptides comprising immunoglobulin single variable domains targeting Glypican-3 and T cell receptor" (Belgian, American Inventors)

Posted On: 2026-08-18

ALEXANDRIA, Va., Aug. 18 -- United States Patent no. 12,709,646, issued on Aug. 18, was assigned to Ablynx NV (Zwijnaarde, Belgium) and Sanofi (Paris).

"Polypeptides comprising immunoglobulin single variable domains targeting Glypican-3 and T cell receptor" was invented by Daniel Janssen (Mortsel, Belgium), Carlo Boutton (Wielsbeke, Belgium), Evelyne Dombrecht (Zwijnaarde, Belgium), Bram Laukens (Zwijnaarde, Belgium), Paolo Meoni (Zwijnaarde, Belgium), Lily Pao (Bridgewater, N.J.), Jan Pype (Herne, Belgium), Peter Schotte (De Pinte, Belgium), Benedikte Serruys (Sint-Michiels, Belgium), Ana Paula Vintem (Zwijnaarde, Belgium) and Diane Van Hoorick (Zwijnaarde, Belgium).

According to the abstract* released by the U.S. Patent & Trademark Offi...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

US Patent Issued to Ablynx, Sanofi on Aug. 18 for "Polypeptides comprising immunoglobulin single variable domains targeting Glypican-3 and T cell receptor" (Belgian, American Inventors)